10x Genomics, Inc. Class A (TXG) Dividend History

Company News

• Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape

  The report highlights the rapid advancements in the molecular diagnostics for cancer market, driven by trends like personalized medicine, pharmacogenomics, and liquid biopsy. It profiles over 140 companies and provides extensive data and forecasts to aid decision-making in this evolving global market.

  GlobeNewswire Inc.

  Featured Companies: A ABT EXAS GH ILMN NTRA QGEN TMO
• Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

  Cathie Wood, the co-founder and CEO of Ark Invest, has been slowing the pace of her portfolio moves lately. However, she still made some notable purchases on Monday, increasing her existing positions in Amazon, GitLab, and 10x Genomics.

  The Motley Fool

  Featured Companies: AMZN GTLB
• 10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates

  10x Genomics reported a Q2 2024 loss of $0.32 per share, beating the Zacks Consensus Estimate of a $0.47 loss. The company's revenue of $153.1 million also surpassed estimates. However, the stock has underperformed the market so far this year.

  Zacks Investment Research

  Featured Companies: KRON
• Cathie Wood's ARK adjusts, buys CrowdStrike stock, sells Tesla By Investing.com - Investing.com Canada

  Cathie Wood's ARK ETFs made significant portfolio adjustments, selling Teladoc shares, increasing CrowdStrike holdings, and reducing Tesla positions.

  Investing.com

  Featured Companies: CRWD OKLO PATH TDOC TSLA
• Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast - Benzinga

  Cathie Wood's Ark Invest reduced its stake in Tesla by $8 million, despite a recent bullish outlook on the company's potential in the autonomous taxi sector.

  Benzinga

  Featured Companies: BEAM GH TSLA